Journal Guide

Primary Care: Clinics in Office Practice updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Each quarterly issue (March, June, September, and December) focuses on a single topic in primary care. Topics covered include allergy and immunology, cardiology, adolescent health, endocrinology, ENT, gastroenterology, geriatrics, hematology/oncology, infectious disease, gynecology and women's health, nephrology, neurology, orthopedics/sports medicine, pediatrics, preventive medicine, psychiatry, rheumatology, and urology.

Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.Research Areas Include:• All major diseases of the lung• Physiology• Pathology• Drug delivery• Metabolism• Pulmonary ToxicologyBefore submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT:1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics.Immediate rejection criteria are: a) Testing of extracts or plant parts that are not characterized b) Case Reports or n=1 studies2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controlsImmediate rejection criteria are: a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human).4. Inappropriate experiments or lacking essential detailImmediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used b) No details of structure if a new drug is used for the first time5. Lack of novelty: The study must represent a novel approach to the field.Immediate rejection criteria are: a) Repetition of well known data b) No advance of knowledge in the fieldNote that only manuscripts written in good English will be considered by the Editors (British usage is preferred).

RSC Chemical Biology is a gold open access journal dedicated to publishing and disseminating exceptional, breakthrough research and high-quality reviews at the interface of chemistry and biology. We welcome contributions from across the breadth of the chemical biology field. This includes Sensing and Imaging, Bioorthogonal chemistry, Biosynthesis, Biomimetics and Bioengineering, Synthetic biology, Directed evolution, Drugs development and mechanism of action, Glycoscience, Natural products, Nucleic acids, Peptides, Phenotypic screening, Proteins (including protein-protein interactions, modifications, structure and function) We are particularly interested in reports on the application of chemical tools to probe, explore and visualize biological systems and processes to provide insights into molecular mechanisms in health and disease. We also encourage translational research that bridges chemistry and chemical biology to medicine.

RSC Medicinal Chemistry publishes significant research in medicinal chemistry and related drug discovery science. Research articles published in RSC Medicinal Chemistry must show a breakthrough or significant advance on previously published work, or bring new thinking or results that will have a strong impact in their field. Topics within the journal's scope include, but are not limited to: design, synthesis and biological evaluation of novel chemical entities or biotherapeutic modalities; modifications of known chemical entities or biotherapeutic modalities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or provide other information of significant value; novel methodologies and technologies in the broader chemical and biological sciences; computational, machine learning and artificial intelligence (AI) studies are welcome where they significantly advance medicinal chemistry knowledge; studies that examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics; studies that present new insights into drug design based on analysis of existing experimental datasets or new theoretical approaches if supported by experimental evidence; studies presenting new drug delivery systems with novel chemical agents are welcomed, in particular those that involve chemical modification of the delivery system of conjugation with novel delivery vectors.

Recent Patents on Anti-Infective Drug Discovery publishes review and research articles, drug clinical trial studies and guest edited thematic issues on recent patents in the field of anti-infective drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to anti-infective drug discovery.

Recent Patents on Anti-Cancer Drug Discovery publishes review/mini review and research articles that reflect or deal with studies in relation to a patent, application of reported patents in a study, discussion of comparison of results regarding application of a given patent, etc., and also guest edited thematic issues on recent patents in the field of anti-cancer drug discovery e.g. on novel bioactive compounds, analogs, targets & predictive biomarkers & drug efficacy biomarkers. The journal also publishes book reviews of eBooks and books on anti-cancer drug discovery. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to anti-cancer drug discovery.

Rheumatology is an international peer review journal publishing the highest quality scientific and clinical papers. The scope of Rheumatology includes a range of rheumatological conditions, musculoskeletal medicine, surgery and translational research. Rheumatology aims to provide very rapid publication of all papers both online and in hard copy.Rheumatology publishes original articles, concise reports, reviews, editorials, guidelines, case reports, clinical vignettes, letters and matters arising from published material.

Despite the major efforts made in oncology over the past ten years, only relatively modest improvements have been made in the conventional treatment of cancer. Recently, a better understanding of molecular pathways has provided pathologists with clues to the parthenogenesis of the disease and multiple targets for new strategies. New treatments, monoclonal antibodies or small molecules, have emerged targeting these pathways and inhibiting tumor growth and progression. These 'mabs' and 'nibs' constitute a new language with its own grammar that oncologists have to learn. Significant work remains in controlling theses processes and understanding these new compounds. This journal aims to be a pragmatic tool for all physicians committed to the field, focusing on insight into the basic science of cellular functions, critical reviews of clinical data. The Société française d'angiogenèse is affiliated to the journal.

The Official Journal of the European Society of Contraception and Reproductive Health, The European Journal of Contraception and Reproductive Health Care publishes original peer-reviewed research papers as well as review papers and other appropriate educational material.The Editors welcome submissions from members of the European Society of Contraception and Reproductive Health and also from non-members anywhere in the world.Peer Review Policy:All published research articles in this journal have undergone rigorous peer review, based on initial editor screening and anonymous reviewing by independent reviewers.

For more than 50 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacology (JCP) for original research, special reviews, commentaries, and case reports on all phases of drug development from absorption, disposition, metabolism, excretion interactions, and preferred uses through post-marketing evaluations.

NOW ON PUBMED!.The journal is aimed at clinicians and researchers from the cardiovascular disease field and will be a forum for all views and reviews relating to this discipline.Topics covered will include: arteriosclerosis, cardiomyopathies, coronary artery disease, diabetes, heart failure, hypertension, metabolic syndrome, obesity, peripheral arterial disease, stroke, arrhythmias, genetics. The purpose of the Journal is to publish (in the English language) articles, reviews and scholarly comment which have been judged worthy of publication by appropriate specialists and accepted by the Editor on studies relating to cardiovascular disease, pharmacology and medicine.

Therapeutic Advances in Drug Safety covers novel and controversial aspects pertaining to the safe use of drugs in patients (drug safety, therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics, regulation). It publishes editorials, perspective reviews, original research (basic and clinical research, negative and positive results), letters, case reports. The Journal encourages the submission of preliminary data and negative studies.

NOW ON PUBMED! Therapeutic Advances in Respiratory Disease is an internationally peer reviewed journal whose primary aim is the dissemination and development of knowledge about the pharmacological treatment of respiratory diseases. The journal`s scope includes emerging therapies for chronic obstructive pulmonary disorder, asthma, pulmonary hypertension and the exacerbations caused by infections and smoking.